Paper Details

  1. Home
  2. Paper Details

Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea.

Author: AhluwaliaGurpreet, BerkDavid R, DoverJeffrey S, DuBoisJanet, JonesTerry M, WeissRobert A

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This phase 2 study evaluated the optimal dosing regimen of oxymetazoline cream for persistent facial erythema of rosacea. 356 patients were randomly assigned to oxymetazoline cream (0.5%, 1.0%, or 1.5%) or vehicle, administered once or twice daily. Oxymetazoline 1.0% once daily provided the optimal dosing regimen.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Rosacea is a chronic dermatologic condition with limited treatment options. OBJECTIVE: This phase 2 study evaluated the optimal oxymetazoline dosing regimen in patients with moderate to severe persistent facial erythema of rosacea. METHODS: Patients were randomly assigned to oxymetazol...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/29537449

データ提供：米国国立医学図書館（NLM）

Oxymetazoline Cream: A Promising Treatment for Rosacea

In the world of [dermatology], the search for effective treatments for [rosacea] is an ongoing quest. This phase 2 study evaluated the efficacy and safety of [oxymetazoline cream] in patients with [moderate to severe persistent facial erythema] associated with [rosacea]. The study aimed to determine the optimal [dosing regimen] for [oxymetazoline cream] in this patient population.

Oxymetazoline Cream Shows Effectiveness in Reducing Erythema

The study demonstrated that [oxymetazoline cream] was effective in reducing [facial erythema] in patients with [rosacea]. The most effective dosing regimen was found to be [oxymetazoline 1.0% once daily]. The study also found that [oxymetazoline cream] was generally well-tolerated, with a safety profile comparable to [vehicle].

Implications for Rosacea Treatment and Patient Care

This research offers a promising new treatment option for patients with [rosacea]. [Oxymetazoline cream] demonstrates effectiveness in reducing [facial erythema], a key symptom of [rosacea]. Further research is needed to evaluate the long-term efficacy and safety of [oxymetazoline cream] for [rosacea] and to compare its effectiveness to other available treatments. Like a camel adapting to the harsh desert sun, patients with rosacea often face persistent challenges. This research offers a glimmer of hope for better management and improved quality of life for those affected by this condition.

Dr. Camel's Conclusion

This research is like a desert flower blooming in a seemingly barren landscape, offering hope for a brighter future for those with rosacea. The potential of oxymetazoline cream to reduce facial erythema and improve quality of life is a significant step forward in dermatological care. As researchers, we must continue to explore innovative treatments and strive for a world where individuals with rosacea can find relief and live fulfilling lives.
Date :
  1. Date Completed 2018-09-05
  2. Date Revised 2018-09-05
Further Info :

Pubmed ID

29537449

DOI: Digital Object Identifier

S1545961618P0308X

Related Literature

Article Analysis
・Effective treatment of rosacea
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.